Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation . Its primary technology platforms are Therapeutic DNA vaccine and hyFc® long-acting technology and bioPROTAC. The company has multiple products in clinical development including several undergoing Phase 3 registrational trials. The company's proprietary pipeline includes GX-188E (tirvalimogene teraplasmid) for head and neck cancer and cervical cancer, GX-I7 (efineptakin alfa) for multiple solid cancers and ARS, GX-H9 (eftansomatropin alfa) for Pediatric Growth Hormone Deficiency and GX-E4 for CKD-induced anemia, among others. in 2024, Genexine has completed a merger with 'EPD biotherapeutics' and acquired future focusing new modality 'bioPROTAC' platform technology which now in pre-clinical development focusing on oncology. The company has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value. Genexine is listed on the Korean exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is committed to the well-being and care of patients worldwide. For more information about Genexine, please visit at www.genexine.com.
We're tracking Genexine, Inc.'s market expansion
How Genexine, Inc.'s international expansion compares to its competitors
Genexine, Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Genexine, Inc.You | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Multiple Korean companies announced significant financial and business decisions, including large contracts, stock issuances, and acquisitions, impacting various sectors such as biotech, energy, and manufacturing.
Korean government increases R&D budget for biotech, focusing on AI-driven antibody development and biobetter projects. Companies like Protina and Genexine are expected to benefit.
Oscotech held an online briefing to explain the necessity of its subsidiary Genexine's IPO and future shareholder return plans, emphasizing it's not a split listing but an essential strategy for R&D funding.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Genexine, Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
